Home › Compare › ENPRF vs ABBV
ENPRF yields 38461.54% · ABBV yields 3.06%● Live data
📍 ENPRF pulled ahead of the other in Year 1
Combined, ENPRF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ENPRF + ABBV for your $10,000?
Current Water Technologies Inc. develops environmental technologies in Canada, Australia, and the United States. It operates through two segments, Current Water and Pumptronics. The company provides patented and proprietary technologies for the treatment of wastewater and drinking water that are contaminated by metals or nutrients, such as arsenic and nitrate/ammonia associated with the mining, metal processing, chemical, agricultural, municipal, and waste management sectors; and for the recovery of nickel and other valuable metals from waste mill sulphide tailings associated with the mining sector. Its technologies include electro-static deionization, a electrochemical process that lowers the concentration of total dissolved solids in water; ammonia removal technology, a technology used for the removal of dissolved ammonia from industrial and municipal water, including wastewater, storm water, sewage effluent, and mine waste water; NitrEL system, an electrochemical water treatment process that reduces nitrate concentrations in contaminated drinking water, groundwater, and industrial process wastewater streams; AmdEl, an electrochemical system that prevents the oxidation of sulphide minerals in tailings or waste rock; and ExtrEL for the recovery of metals from sulphide tailings and ore. The company was formerly known as ENPAR Technologies Inc. and changed its name to Current Water Technologies Inc. in January 2018. Current Water Technologies Inc. was incorporated in 1996 and is headquartered in Guelph, Canada.
Full ENPRF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.